1 |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1):7-30.
|
2 |
CHEN W, ZHENG R, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
|
3 |
PATRU C L, SURLIN V, GEORGESCU I, et al. Current issues in gastric cancer epidemiology[J]. Rev Med Chir Soc Med Nat Iasi, 2013,117(1):199-204.
|
4 |
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma[J]. Nature, 2014, 513(7517):202-209.
|
5 |
KATONA B W, RUSTGI A K. Gastric cancer genomics: advances and future directions[J]. Cell Mol Gastroenterol Hepatol, 2017, 3(2):211-217.
|
6 |
WEBER G F, WAXMAN D J. Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes[J]. Biochem Pharmacol, 1993, 45(8):1685-1694.
|
7 |
GHOSHAL U, TRIPATHI S, KUMAR S, et al. Genetic polymorphism of cytochrome P450 (CYP) 1A1, CYP1A2, and CYP2E1 genes modulate susceptibility to gastric cancer in patients with Helicobacter pylori infection[J]. Gastric Cancer, 2014, 17(2):226-234.
|
8 |
ZHANG M X, LIU K, WANG F G, et al. Association between CYP2E1 polymorphisms and risk of gastric cancer: an updated meta-analysis of 32 case-control studies[J]. Mol Clin Oncol, 2016, 4(6):1031-1038.
|
9 |
LI J, DING Y, LI A. Identification of COL1A1 and COL1A2 as candidate prognostic factors in gastric cancer[J]. World J Surg Oncol, 2016, 14(1):297.
|
10 |
HIDAKA A, SASAZUKI S, MATSUO K, et al. CYP1A1, GSTM1 and GSTT1 genetic polymorphisms and gastric cancer risk among Japanese: a nested case-control study within a large-scale population-based prospective study[J]. Int J Cancer, 2016, 139(4):759-768.
|
11 |
NEGOVAN A, IANCU M, MOLDOVAN V, et al. The interaction between GSTT1, GSTM1, and GSTP1 Ile105Val gene polymorphisms and environmental risk factors in premalignant gastric lesions risk[J]. Biomed Res Int, 2017, 2017:7365080.
|
12 |
JO J C, LEE J L, RYU M H, et al. Phase Ⅱ and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer[J]. Br J Cancer, 2012, 106(10):1591-1597.
|
13 |
WANG W, HUANG J, TAO Y, et al. Phase Ⅱand UGT1A1 polymorphism study of two different irinotecan dosages combined with cisplatin as first-line therapy for advanced gastric cancer[J]. Chemotherapy, 2016, 61(4):197-203.
|
14 |
PATEL M, LU L, ZANDER D S, et al. ALDH1A1 and ALDH3A1 expression in lung cancers: correlation with histologic type and potential precursors[J]. Lung Cancer, 2008, 59(3):340-349.
|
15 |
袁青, 薛亚东, 郑雅萍,等. 乙醛脱氢酶2基因多态性及生活习惯与胃癌易感性的相关性分析[J]. 检验医学, 2016, 31(7):584-587.
|
16 |
SHIMIZU T, TOLCHER A W, PAPADOPOULOS K P,et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer[J]. Clin Cancer Res, 2012, 18(8):2316-2325.
|
17 |
LI Y, HE W, LIU T, et al. A new cyclo-oxygenase-2 gene variant in the Han Chinese population is associated with an increased risk of gastric carcinoma[J]. Mol Diagn Ther, 2010, 14(6):351-355.
|